Compare Global X Robotics and Artificial Intelligence ETF (BOTZ) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Robotics and Artificial Intelligence ETF vs Gilead Sciences, Inc. — how do they compare? Global X Robotics and Artificial Intelligence ETF trades at $37.48, while Gilead Sciences, Inc. trades at $135.89 (market cap $164.99B). The key difference: Gilead Sciences, Inc. pays a 2.47% dividend while Global X Robotics and Artificial Intelligence ETF pays none. Which is the better fit depends on your goals.
| BOTZ | GILD | |
|---|---|---|
52-Week High | $41.63 | $155.80 |
52-Week Low | $31.99 | $110.56 |
Market Cap | — | $164.99B |
Sector | — | Health |
Enterprise Value | — | $188.06B |
Dividend Yield | — | 2.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BOTZ trades at $37.61, up 1.81% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF focuses on robotics and AI, offering exposure to global leaders in automation. Recent news highlights its role in the expanding AI and robotics theme, with comparisons to peers like ARKQ and ROBO. A small dividend is scheduled for 2026.
Outlook is positive due to growth in AI and robotics adoption, but risks include high valuation sensitivity and sector competition. Investors should weigh the thematic growth potential against market volatility and the ETF's expense structure.
Gilead Sciences (GILD) trades at $133.21, up 1.8% in the last session, with a bullish technical outlook and strong analyst support. Recent Q2 2026 results showed a revenue beat despite a net loss driven by acquisition costs, with HIV drug sales and pipeline progress fueling raised full-year guidance. The stock exhibits robust cash flow from operations and a high gross margin, though negative net income and elevated debt levels present fundamental concerns.
The outlook is positive based on raised sales guidance and pipeline momentum, but risks include patent cliffs for key HIV drugs by the mid-2030s and integration challenges from recent acquisitions. With a consensus price target of $151.22 implying 13.5% upside, Wall Street sentiment is bullish, though investors should weigh growth prospects against execution and regulatory risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Robotics and Artificial Intelligence ETF
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that are involved in the development of robotics and/or artificial intelligence. The fund is non-diversified.
Read more on BOTZ →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
